Bonadonna G, Santoro A, Gianni A M, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonfante V, Gianni L
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Ann Oncol. 1991 Jan;2 Suppl 1:9-16. doi: 10.1093/annonc/2.suppl_1.9.
This paper reviews the most relevant therapeutic results achieved by the Milan Cancer Institute through successive randomized studies in advanced Hodgkin's disease. The experience achieved confirms the therapeutic importance of an anthracycline-containing regimen such as ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment and as primary chemotherapy, either when combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone). Anthracycline-based combinations can be further refined to decrease toxicity. The biologic aspects of drug-sensitive v drug-resistant tumor cells and the accurate definition of prognostic categories at the time of first treatment failure are also discussed.
本文回顾了米兰癌症研究所在晚期霍奇金病连续随机研究中取得的最相关治疗成果。所取得的经验证实了含蒽环类药物方案（如ABVD，即阿霉素/博来霉素/长春花碱/达卡巴嗪）作为挽救治疗和一线化疗的治疗重要性，无论是与放疗联合使用，还是与MOPP（氮芥/长春新碱/丙卡巴肼/泼尼松）循环交替使用。基于蒽环类药物的联合方案可进一步优化以降低毒性。还讨论了药物敏感与耐药肿瘤细胞的生物学方面以及首次治疗失败时预后类别的准确定义。
